Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LRMR
LRMR | US
3.30
USD-0.21
-5.98%
LRMR | US
About LRMR
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
3.30
Open
3.47
High
3.48
Low
3.30
Larimar Therapeutics Inc. a clinical-stage biotechnology company focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601 which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia a rare progressive and fatal genetic disease. The company is headquartered in Bala Cynwyd Pennsylvania.
View LessLRMR | US
Risk
68.8
Sharpe
0.37
Luna's Score
49/100
Recommendation
Hold
Luna says (LRMR | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
51.7%1 month
68.8%3 months
63.1%6 months
118.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.33
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
-4.13
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-65.51M
MarketCap
210.56M
MarketCap(USD)
210.56M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-37.48
Short ratio
4.63
Short perc.
8.57
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.46
Range1M
1.07
Range3M
2.79
Volumes: Market Activity
Rel. volume
0.98
Price X volume
5.85M
